Literature DB >> 32947956

Regulation of Poly(ADP-Ribose) Polymerase 1 Activity by Y-Box-Binding Protein 1.

Konstantin N Naumenko1, Mariya V Sukhanova1, Loic Hamon2, Tatyana A Kurgina1,3, Elizaveta E Alemasova1, Mikhail M Kutuzov1, David Pastré2, Olga I Lavrik1,3.   

Abstract

Y-box-binding protein 1 (YB-1) is a multifunctional positively charged protein that interacts with DNA or RNA and poly(ADP-ribose) (PAR). YB-1 is poly(ADP-ribosyl)ated and stimulates poly(ADP-ribose) polymerase 1 (PARP1) activity. Here, we studied the mechanism of YB-1-dependent PAR synthesis by PARP1 in vitro using biochemical and atomic force microscopy assays. PAR synthesis activity of PARP1 is known to be facilitated by co-factors such as Mg2+. However, in contrast to an Mg2+-dependent reaction, the activation of PARP1 by YB-1 is accompanied by overall up-regulation of protein PARylation and shortening of the PAR polymer. Therefore, YB-1 and cation co-factors stimulated PAR synthesis in divergent ways. PARP1 autoPARylation in the presence of YB-1 as well as trans-PARylation of YB-1 are greatly affected by the type of damaged DNA, suggesting that PARP1 activation depends on the formation of a PARP1-YB-1-DNA ternary complex. An unstructured C-terminal part of YB-1 involved in an interaction with PAR behaves similarly to full-length YB-1, indicating that both DNA and PAR binding are involved in the stimulation of PARP1 activity by YB-1. Thus, YB-1 is likely linked to the regulation of PARylation events in cells via an interaction with PAR and damaged DNA.

Entities:  

Keywords:  Y-box-binding protein 1; poly(ADP-ribose) polymerase 1; protein poly(ADP-ribosyl)ation

Year:  2020        PMID: 32947956      PMCID: PMC7565162          DOI: 10.3390/biom10091325

Source DB:  PubMed          Journal:  Biomolecules        ISSN: 2218-273X


  74 in total

1.  The nucleosomal core histone octamer at 3.1 A resolution: a tripartite protein assembly and a left-handed superhelix.

Authors:  G Arents; R W Burlingame; B C Wang; W E Love; E N Moudrianakis
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

2.  Nuclear translocation of the Y-box binding protein by ultraviolet irradiation.

Authors:  K Koike; T Uchiumi; T Ohga; S Toh; M Wada; K Kohno; M Kuwano
Journal:  FEBS Lett       Date:  1997-11-17       Impact factor: 4.124

Review 3.  Nuclear ADP-Ribosylation and Its Role in Chromatin Plasticity, Cell Differentiation, and Epigenetics.

Authors:  Michael O Hottiger
Journal:  Annu Rev Biochem       Date:  2015-02-26       Impact factor: 23.643

Review 4.  Structural and functional properties of the evolutionarily ancient Y-box family of nucleic acid binding proteins.

Authors:  A P Wolffe
Journal:  Bioessays       Date:  1994-04       Impact factor: 4.345

Review 5.  Regulation of poly(ADP-ribose) metabolism by poly(ADP-ribose) glycohydrolase: where and when?

Authors:  M-E Bonicalzi; J-F Haince; A Droit; G G Poirier
Journal:  Cell Mol Life Sci       Date:  2005-04       Impact factor: 9.261

Review 6.  Y-box-binding protein 1 (YB-1) and its functions.

Authors:  I A Eliseeva; E R Kim; S G Guryanov; L P Ovchinnikov; D N Lyabin
Journal:  Biochemistry (Mosc)       Date:  2011-12       Impact factor: 2.487

Review 7.  The PARP superfamily.

Authors:  Jean-Christophe Amé; Catherine Spenlehauer; Gilbert de Murcia
Journal:  Bioessays       Date:  2004-08       Impact factor: 4.345

8.  Single molecule detection of PARP1 and PARP2 interaction with DNA strand breaks and their poly(ADP-ribosyl)ation using high-resolution AFM imaging.

Authors:  Maria V Sukhanova; Sanae Abrakhi; Vandana Joshi; David Pastre; Mikhail M Kutuzov; Rashid O Anarbaev; Patrick A Curmi; Loic Hamon; Olga I Lavrik
Journal:  Nucleic Acids Res       Date:  2015-12-15       Impact factor: 16.971

9.  The C-terminal domain of p53 orchestrates the interplay between non-covalent and covalent poly(ADP-ribosyl)ation of p53 by PARP1.

Authors:  Arthur Fischbach; Annika Krüger; Stephanie Hampp; Greta Assmann; Lisa Rank; Matthias Hufnagel; Martin T Stöckl; Jan M F Fischer; Sebastian Veith; Pascal Rossatti; Magdalena Ganz; Elisa Ferrando-May; Andrea Hartwig; Karin Hauser; Lisa Wiesmüller; Alexander Bürkle; Aswin Mangerich
Journal:  Nucleic Acids Res       Date:  2018-01-25       Impact factor: 16.971

10.  Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin.

Authors:  Hana Hanzlikova; William Gittens; Katerina Krejcikova; Zhihong Zeng; Keith W Caldecott
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

View more
  6 in total

1.  The C-Terminal Domain of Y-Box Binding Protein 1 Exhibits Structure-Specific Binding to Poly(ADP-Ribose), Which Regulates PARP1 Activity.

Authors:  Konstantin N Naumenko; Mariya V Sukhanova; Loic Hamon; Tatyana A Kurgina; Rashid O Anarbaev; Aswin Mangerich; David Pastré; Olga I Lavrik
Journal:  Front Cell Dev Biol       Date:  2022-06-21

2.  DNA Damage Response.

Authors:  Valentyn Oksenych; Denis E Kainov
Journal:  Biomolecules       Date:  2021-01-19

3.  NAD+ bioavailability mediates PARG inhibition-induced replication arrest, intra S-phase checkpoint and apoptosis in glioma stem cells.

Authors:  Jianfeng Li; Kate M Saville; Md Ibrahim; Xuemei Zeng; Steve McClellan; Anusha Angajala; Alison Beiser; Joel F Andrews; Mai Sun; Christopher A Koczor; Jennifer Clark; Faisal Hayat; Mikhail V Makarov; Anna Wilk; Nathan A Yates; Marie E Migaud; Robert W Sobol
Journal:  NAR Cancer       Date:  2021-11-17

4.  Dual function of HPF1 in the modulation of PARP1 and PARP2 activities.

Authors:  Tatyana A Kurgina; Nina A Moor; Mikhail M Kutuzov; Konstantin N Naumenko; Alexander A Ukraintsev; Olga I Lavrik
Journal:  Commun Biol       Date:  2021-11-03

Review 5.  YB-1 as an Oncoprotein: Functions, Regulation, Post-Translational Modifications, and Targeted Therapy.

Authors:  Qiyan Yin; Min Zheng; Qianmei Luo; Dewei Jiang; Huifeng Zhang; Ceshi Chen
Journal:  Cells       Date:  2022-04-04       Impact factor: 6.600

6.  An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.

Authors:  Jing Xu; Yi Gao; Xiaotian Luan; Ke Li; Jing Wang; Yilin Dai; Mingyi Kang; Chong Lu; Minhua Zhang; Chris X Lu; Yu Kang; Congjian Xu
Journal:  Cancer Chemother Pharmacol       Date:  2022-04-13       Impact factor: 3.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.